

# Joel Tarning

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9367589/joel-tarning-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

154  
papers

8,426  
citations

35  
h-index

90  
g-index

169  
ext. papers

10,029  
ext. citations

8  
avg, IF

5.43  
L-index

#	Paper	IF	Citations
154	Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis.. <i>Malaria Journal</i> , <b>2022</b> , 21, 106	3.6	0
153	Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing.. <i>PLoS Neglected Tropical Diseases</i> , <b>2022</b> , 16, e0010289	4.8	1
152	Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside.. <i>PLoS Neglected Tropical Diseases</i> , <b>2022</b> , 16, e0010219	4.8	0
151	Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy.. <i>AAPS Journal</i> , <b>2022</b> , 24, 48	3.7	
150	Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial.. <i>Lancet Infectious Diseases</i> , <b>2022</b> ,	25.5	3
149	The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern.. <i>Nature Communications</i> , <b>2022</b> , 13, 719	17.4	11
148	Response to "Pharmacometric Approach to Evaluate Drug Dosing Adherence". <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 24-25	6.1	
147	Assessment of the amino acid profile in Thai patients with type 2 diabetes mellitus using liquid chromatography-mass spectrometry. <i>International Health</i> , <b>2021</b> , 13, 367-373	2.4	1
146	Pharmacokinetic Study of Rectal Artesunate in Children with Severe Malaria in Africa. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , 65,	5.9	3
145	Structure-switching aptamer sensors for the specific detection of piperazine and mefloquine. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	7
144	High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab267		3
143	Study protocol: an open-label individually randomised controlled trial to assess the efficacy of artemether-lumefantrine prophylaxis for malaria among forest goers in Cambodia. <i>BMJ Open</i> , <b>2021</b> , 11, e045900	3	3
142	Identification of the metabolites of ivermectin in humans. <i>Pharmacology Research and Perspectives</i> , <b>2021</b> , 9, e00712	3.1	8
141	Piperazine Pharmacokinetics during Intermittent Preventive Treatment for Malaria in Pregnancy. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , 65,	5.9	2
140	A Physiologically-Based Pharmacokinetic Framework for Prediction of Drug Exposure in Malnourished Children. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	2
139	High-throughput quantitation method for amodiaquine and desethylamodiaquine in plasma using supported liquid extraction technology. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2021</b> , 1179, 122887	3.2	0
138	Determinants of Primaquine and Carboxyprimaquine Exposures in Children and Adults with Plasmodium vivax Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , 65, e0130221	5.9	3

137	Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria. <i>Malaria Journal</i> , <b>2021</b> , 20, 366	3.6	2
136	Metabolomics reveal alterations in arachidonic acid metabolism in <i>Schistosoma mekongi</i> after exposure to praziquantel. <i>PLoS Neglected Tropical Diseases</i> , <b>2021</b> , 15, e0009706	4.8	0
135	Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial. <i>Lancet Infectious Diseases, The</i> , <b>2021</b> , 21, 1395-1406	25.5	9
134	A Randomized Controlled Trial of Three- versus Five-Day Artemether-Lumefantrine Regimens for Treatment of Uncomplicated <i>Plasmodium falciparum</i> Malaria in Pregnancy in Africa. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	11
133	Pooled Multicenter Analysis of Cardiovascular Safety and Population Pharmacokinetic Properties of Piperaquine in African Patients with Uncomplicated <i>Falciparum</i> Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	2
132	Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated <i>falciparum</i> malaria in pregnancy: a systematic review and individual patient data meta-analysis. <i>Lancet Infectious Diseases, The</i> , <b>2020</b> , 20, 943-952	25.5	14
131	Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by c.516G>T Genotypes. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	3
130	Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated <i>Plasmodium falciparum</i> malaria: a multicentre, open-label, randomised clinical trial. <i>Lancet, The</i> , <b>2020</b> , 395, 1345-1360	40	93
129	Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003040	11.6	12
128	High-Dose Chloroquine for Uncomplicated <i>Plasmodium falciparum</i> Malaria Is Well Tolerated and Causes Similar QT Interval Prolongation as Standard-Dose Chloroquine in Children. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	19
127	Pharmacokinetics and Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 1023-1033	6.1	15
126	Concentration-dependent mortality of chloroquine in overdose. <i>ELife</i> , <b>2020</b> , 9,	8.9	17
125	Safety, Pharmacokinetics, and Mosquito-Lethal Effects of Ivermectin in Combination With Dihydroartemisinin-Piperaquine and Primaquine in Healthy Adult Thai Subjects. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 1221-1230	6.1	17
124	Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used for Seasonal Malaria Chemoprevention in African Children. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 1179-1188	6.1	9
123	CYP2B6*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , <b>2020</b> , 60, 351-360	2.9	1
122	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 2030-2040	59.2	628
121	Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. <i>EBioMedicine</i> , <b>2020</b> , 62, 103125	8.8	17
120	Population Pharmacokinetic Properties of Antituberculosis Drugs in Vietnamese Children with Tuberculous Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 65,	5.9	3

119	COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003252	11.6	55
118	Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperazine, and primaquine in healthy Thai adult volunteers. <i>Human Vaccines and Immunotherapeutics</i> , <b>2020</b> , 16, 33-41	4.4	4
117	An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	4
116	A validation study of microscopy versus quantitative PCR for measuring parasitemia. <i>Tropical Medicine and Health</i> , <b>2019</b> , 47, 49	3.4	2
115	Optimal dosing of dihydroartemisinin-piperazine for seasonal malaria chemoprevention in young children. <i>Nature Communications</i> , <b>2019</b> , 10, 480	17.4	13
114	Pharmacokinetic-Pharmacodynamic Assessment of the Hepatic and Bone Marrow Toxicities of the New Trypanoside Fexinidazole. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	13
113	Sequential Open-Label Study of the Safety, Tolerability, and Pharmacokinetic Interactions between Dihydroartemisinin-Piperazine and Mefloquine in Healthy Thai Adults. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	7
112	Severe Acute Malnutrition Results in Lower Lumefantrine Exposure in Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 1299-1309	6.1	17
111	Amino acid derangements in adults with severe falciparum malaria. <i>Scientific Reports</i> , <b>2019</b> , 9, 6602	4.9	6
110	High sensitivity methods to quantify chloroquine and its metabolite in human blood samples using LC-MS/MS. <i>Bioanalysis</i> , <b>2019</b> , 11, 333-347	2.1	18
109	Pooled Population Pharmacokinetic Analysis of Tribendimidine for the Treatment of Infections. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	5
108	Determinants of dihydroartemisinin-piperazine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. <i>Lancet Infectious Diseases</i> , <b>2019</b> , 19, 952-961	25.5	160
107	Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated malaria in Burkina Faso: an open label trial. <i>Wellcome Open Research</i> , <b>2019</b> , 4, 45	4.8	1
106	Pharmacokinetics of oral tenofovir disoproxil fumarate in pregnancy and lactation: a systematic review. <i>Antiviral Therapy</i> , <b>2019</b> , 24, 529-540	1.6	4
105	Modeling the dynamics of gametocytes in humans during malaria infection. <i>ELife</i> , <b>2019</b> , 8,	8.9	15
104	Clinically Relevant Drug Interactions for Malaria <b>2019</b> , 1-11		
103	Piperazine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperazine. <i>BMC Infectious Diseases</i> , <b>2019</b> , 19, 1025	4	4
102	Chloroquine Versus Dihydroartemisinin-Piperazine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 1311-1319	11.6	32

101	Identifying the Components of Acidosis in Patients With Severe Plasmodium falciparum Malaria Using Metabolomics. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 219, 1766-1776	7	19
100	Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	7
99	Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 644-654	3.8	10
98	Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	9
97	Characterizing Blood-Stage Antimalarial Drug MIC Values Using Reinfection Patterns. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	9
96	Treatment of uncomplicated and severe malaria during pregnancy. <i>Lancet Infectious Diseases</i> , <b>2018</b> , 18, e133-e146	25.5	18
95	Primaquine Pharmacokinetics in Lactating Women and Breastfed Infant Exposures. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 1000-1007	11.6	16
94	Acetaminophen as a Renoprotective Adjunctive Treatment in Patients With Severe and Moderately Severe Falciparum Malaria: A Randomized, Controlled, Open-Label Trial. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 991-999	11.6	28
93	Model-Informed Drug Development for Malaria Therapeutics. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2018</b> , 58, 567-582	17.9	15
92	Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	10
91	Acidosis and acute kidney injury in severe malaria. <i>Malaria Journal</i> , <b>2018</b> , 17, 128	3.6	5
90	Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar. <i>Malaria Journal</i> , <b>2018</b> , 17, 126	3.6	11
89	Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	12
88	Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 3102-3113	5.1	12
87	Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 1543-1549	11.6	40
86	Promising approach to reducing Malaria transmission by ivermectin: Sporontocidal effect against Plasmodium vivax in the South American vectors Anopheles aquasalis and Anopheles darlingi. <i>PLoS Neglected Tropical Diseases</i> , <b>2018</b> , 12, e0006221	4.8	26
85	Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. <i>PLoS Medicine</i> , <b>2018</b> , 15, e1002579	11.6	28
84	Quantitation of paracetamol by liquid chromatography-mass spectrometry in human plasma in support of clinical trial. <i>Future Science OA</i> , <b>2018</b> , 4, FSO331	2.7	3

83	Effect of Antiretroviral Therapy on Plasma Concentrations of Chloroquine and Desethyl-chloroquine. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 1617-1620	11.6	3
82	Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	12
81	Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia. <i>AAPS Journal</i> , <b>2017</b> , 19, 1842-1854	3.7	8
80	Treatment Failure of Dihydroartemisinin/Piperaquine for Plasmodium falciparum Malaria, Vietnam. <i>Emerging Infectious Diseases</i> , <b>2017</b> , 23, 715-717	10.2	63
79	Inhibition of merozoite invasion and transient de-sequestration by sevuparin in humans with Plasmodium falciparum malaria. <i>PLoS ONE</i> , <b>2017</b> , 12, e0188754	3.7	27
78	Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles. <i>Malaria Journal</i> , <b>2017</b> , 16, 280	3.6	31
77	In vitro antioxidant and antimalarial activities of leaves, pods and bark extracts of Acacia nilotica (L.) Del. <i>BMC Complementary and Alternative Medicine</i> , <b>2017</b> , 17, 372	4.7	22
76	Quantification of the antimalarial drug pyronaridine in whole blood using LC-MS/MS - Increased sensitivity resulting from reduced non-specific binding. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2017</b> , 146, 214-219	3.5	5
75	Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 2752-2766	3.8	22
74	Estimation of the In Vivo MIC of Cipargamin in Uncomplicated Plasmodium falciparum Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	23
73	Antibacterial Activities and Possible Modes of Action of Acacia nilotica (L.) Del. against Multidrug-Resistant Escherichia coli and Salmonella. <i>Molecules</i> , <b>2017</b> , 22,	4.8	38
72	Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. <i>PLoS Medicine</i> , <b>2017</b> , 14, e1002212	11.6	35
71	Clinical presentations, diagnosis, mortality and prognostic markers of tuberculous meningitis in Vietnamese children: a prospective descriptive study. <i>BMC Infectious Diseases</i> , <b>2016</b> , 16, 573	4	26
70	Population Pharmacokinetic Modeling of Tribendimidine Metabolites in Opisthorchis viverrini-Infected Adults. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 5695-704	5.9	6
69	Population pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteers. <i>Malaria Journal</i> , <b>2016</b> , 15, 90	3.6	17
68	Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction. <i>Malaria Journal</i> , <b>2016</b> , 15, 121	3.6	6
67	Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. <i>Lancet Infectious Diseases</i> , <b>2016</b> , 16, 357-65	25.5	307
66	Name-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis. <i>BMC Infectious Diseases</i> , <b>2016</b> , 16, 144	4	29

65	Pharmacokinetic properties of intramuscular versus oral syrup paracetamol in Plasmodium falciparum malaria. <i>Malaria Journal</i> , <b>2016</b> , 15, 244	3.6	3
64	Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 1103-12	3.8	15
63	The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. <i>BMC Medicine</i> , <b>2015</b> , 13, 66	11.4	31
62	Screening of phytochemicals and in vitro evaluation of antibacterial and antioxidant activities of leaves, pods and bark extracts of <i>Acacia nilotica</i> (L.) Del.. <i>Industrial Crops and Products</i> , <b>2015</b> , 77, 873-882	5.9	56
61	Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 4387-96	5.9	35
60	Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 6375-84	5.9	19
59	Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 79, 636-49	3.8	38
58	Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 80, 642-53	3.8	24
57	The role of previously unmeasured organic acids in the pathogenesis of severe malaria. <i>Critical Care</i> , <b>2015</b> , 19, 317	10.8	12
56	Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 4719-26	5.9	211
55	Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 505-13	5.9	32
54	Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 2499-507	5.1	26
53	Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 1615-21	5.9	16
52	Statistical power calculations for mixed pharmacokinetic study designs using a population approach. <i>AAPS Journal</i> , <b>2014</b> , 16, 1110-8	3.7	6
51	Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 3033-40	5.1	17
50	Efficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquine. <i>PLoS ONE</i> , <b>2014</b> , 9, e103200	3.7	13
49	Spread of artemisinin resistance in Plasmodium falciparum malaria. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 411-23	59.2	1366
48	Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. <i>Nature Communications</i> , <b>2014</b> , 5, 5606	17.4	62

47	Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 7340-6	5.9	38
46	Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 2052-8	5.9	20
45	Randomized comparison of the efficacies and tolerabilities of three artemisinin-based combination treatments for children with acute Plasmodium falciparum malaria in the Democratic Republic of the Congo. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 5528-36	5.9	28
44	Pharmacokinetic interactions between primaquine and chloroquine. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 3354-9	5.9	68
43	Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 1370-6	5.1	13
42	Benefits of a pharmacology antimalarial reference standard and proficiency testing program provided by the Worldwide Antimalarial Resistance Network (WWARN). <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 3889-94	5.9	23
41	Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 260ra147	17.5	17
40	Liquid chromatographic-mass spectrometric method for simultaneous determination of small organic acids potentially contributing to acidosis in severe malaria. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2013</b> , 941, 116-22	3.2	30
39	A robust design for identification of the Parasite Clearance Estimator. <i>Malaria Journal</i> , <b>2013</b> , 12, 410	3.6	5
38	Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. <i>Journal of Clinical Pharmacology</i> , <b>2013</b> , 53, 119-39	2.9	45
37	Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 5096-103	5.9	37
36	Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, e48-58	11.6	45
35	Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. <i>Journal of Infectious Diseases</i> , <b>2013</b> , 207, 842-7	7	82
34	Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in Tanzanian children with severe Falciparum malaria. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 775-83	5.9	9
33	Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. <i>PLoS ONE</i> , <b>2013</b> , 8, e57689	3.7	163
32	Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 377-86	1.6	53
31	The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 74, 932-9	3.8	21
30	A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. <i>Malaria Journal</i> , <b>2012</b> , 11, 398	3.6	36



29	Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. <i>Malaria Journal</i> , <b>2012</b> , 11, 293	3.6	36
28	Optimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malaria. <i>Malaria Journal</i> , <b>2012</b> , 11, 143	3.6	14
27	Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 73, 467-77	3.8	49
26	Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 2213-21	5.1	70
25	Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 1217-23	5.1	33
24	Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 5764-73	5.9	35
23	Population pharmacokinetics of dihydroartemisinin and piperazine in pregnant and nonpregnant women with uncomplicated malaria. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 1997-2007	5.9	80
22	Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperazine chemoprevention in adults at high risk of malaria. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 1571-7	5.9	54
21	Pharmacokinetics of piperazine in pregnant women in Sudan with uncomplicated Plasmodium falciparum malaria. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2012</b> , 87, 35-40	3.2	33
20	Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study. <i>Clinical Therapeutics</i> , <b>2011</b> , 33, 644-54	3.5	17
19	Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria. <i>Malaria Journal</i> , <b>2011</b> , 10, 181	3.6	13
18	Intrahost modeling of artemisinin resistance in Plasmodium falciparum. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 397-402	11.5	131
17	Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 4338-42	5.9	36
16	A small amount of fat does not affect piperazine exposure in patients with malaria. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 3971-6	5.9	26
15	Pharmacokinetics of dihydroartemisinin and piperazine in pregnant and nonpregnant women with uncomplicated falciparum malaria. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 5500-6	5.9	50
14	Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine. <i>Malaria Journal</i> , <b>2010</b> , 9, 275	3.6	24
13	Comparison of plasma, venous and capillary blood levels of piperazine in patients with uncomplicated falciparum malaria. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 705-12	2.8	28
12	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 3837-46	5.9	88

11	Artemisinin resistance in Plasmodium falciparum malaria. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 455-67	59.2	2437
10	Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria?. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2009</b> , 80, 126-32	3.2	16
9	Does Artesunate Prolong the Electrocardiograph QT Interval in Patients with Severe Malaria?. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2009</b> , 80, 126-132	3.2	26
8	Quantification of the antimalarial piperazine in plasma. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , <b>2008</b> , 102, 409-11	2	7
7	Pitfalls in estimating piperazine elimination. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2005</b> , 49, 5127-8	5.9	57
6	Determination of ceftriaxone in human plasma using liquid chromatography tandem mass spectrometry. <i>Wellcome Open Research</i> , <b>4</b> , 47	4.8	4
5	Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Burkina Faso: an open label trial. <i>Wellcome Open Research</i> , <b>4</b> , 45	4.8	
4	Concentration-dependent mortality of chloroquine in overdose		2
3	Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial		82
2	Determination of ceftriaxone in human plasma using liquid chromatography tandem mass spectrometry. <i>Wellcome Open Research</i> , <b>4</b> , 47	4.8	1
1	Determination of ceftriaxone in human plasma using liquid chromatography tandem mass spectrometry. <i>Wellcome Open Research</i> , <b>4</b> , 47	4.8	0